Dietary supplements comprising at least one probiotic and at least one of animal digest, dried brewers yeast, vitamin C; vitamin E, beta carotene, zinc proteinate, manganese proteinate, ferrous sulfate, copper proteinate, calcium iodate, and sodium selenite. The probiotics and other ingredients are present in the supplement in amounts sufficient to enhance the palatability of the probiotics and compositions containing the probiotics, enhance the immune system to augment the beneficial effects of the probiotics, or extend the life of the probiotics.

Dietary supplements comprising at least one probiotic and at least one of animal digest, dried brewers yeast, vitamin C; vitamin E, beta carotene, zinc proteinate, manganese proteinate, ferrous sulfate, copper proteinate, calcium iodate, and sodium selenite. The probiotics and other ingredients are present in the supplement in amounts sufficient to enhance the palatability of the probiotics and compositions containing the probiotics, enhance the immune system to augment the beneficial effects of the probiotics, or extend the life of the probiotics.

The present invention provides a pet chew, comprising edible glue, vegetable protein, humectant, dispersant agent, crosslinking agent, flavor substance, functional substance, nutrient and water, wherein the edible glue comprises gelatin, vegetable glue or a compound of the gelatin and the vegetable glue. The present invention further provides a preparation method of the foregoing pet chew. The pet chew provided by the present invention does not contain stodgy animal skins and the crosslinking reaction occurs under a specific process to combine some beneficial ingredients, such that the pet chew has a plurality of specific functions, has a relatively good flavor and relatively high palatability, and is more interesting and entertaining.

Food formulations and manufacturing process thereof, which introduce food fibers, resulting from residues of other industrial processes, into animal feed. Where these fibers help reduce the apparent digestibility coefficient, conferring a dietary pattern to animal feed, in addition to the manufacturing process of the feed.

The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like. It was confirmed that the novel magnesium-serinate composition obtained by the production method of the present invention consisted of about 10% magnesium and about 90% serine, as determined by instrumental analysis, was solubilized at a concentration of about 500 mg/ml in water at room temperature at a pH of 6.0 to 10.0, was maintained in an aqueous solution state without forming a precipitate, and was also solubilized at a concentration of about 500 mg/ml in phosphate-buffered saline (PBS) solution at room temperature without forming a precipitate. Thus, the novel magnesium-serinate composition has properties suitable for administration orally or by injection to the human body. In addition, the compound activates mitochondrial function and neuronal cell proliferation by increasing the oxygen consumption rate of mitochondria, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, etc.

The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like. It was confirmed that the novel magnesium-serinate composition obtained by the production method of the present invention consisted of about 10% magnesium and about 90% serine, as determined by instrumental analysis, was solubilized at a concentration of about 500 mg/ml in water at room temperature at a pH of 6.0 to 10.0, was maintained in an aqueous solution state without forming a precipitate, and was also solubilized at a concentration of about 500 mg/ml in phosphate-buffered saline (PBS) solution at room temperature without forming a precipitate. Thus, the novel magnesium-serinate composition has properties suitable for administration orally or by injection to the human body. In addition, the compound activates mitochondrial function and neuronal cell proliferation by increasing the oxygen consumption rate of mitochondria, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, etc.

The present invention is concerned with increasing protein intake in a ruminant animal by supplementing the diet of the ruminant animal with urea phosphate. There can also be supplementation with a water soluble sulfur-containing salt such as ammonium sulfate. Urea can be administered together with urea phosphate. The composition provides a slow release form of urea that avoids inducing ammonia toxicity in the animal and is water soluble for administration to the animal in drinking water.

The present invention is concerned with increasing protein intake in a ruminant animal by supplementing the diet of the ruminant animal with urea phosphate. There can also be supplementation with a water soluble sulfur-containing salt such as ammonium sulfate. Urea can be administered together with urea phosphate. The composition provides a slow release form of urea that avoids inducing ammonia toxicity in the animal and is water soluble for administration to the animal in drinking water.

A deer family antler pet chew includes one or more additives present in an effective amount in the deer family antler to improve at least the health of a dog ingesting the deer family antler dog chew. The one or more additives can be added to the dog chew using an infusion technique.

A deer family antler pet chew includes one or more additives present in an effective amount in the deer family antler to improve at least the health of a dog ingesting the deer family antler dog chew. The one or more additives can be added to the dog chew using an infusion technique.